Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Mirati Therapeutics history
Mirati Therapeutics company history timeline
In 2014, Mirati & Array set out to create a successful molecule.
Ostrem, Jonathan M., Shokat, Kevan M. “Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.” Nat Rev Drug Discov 15.11 (2016): 771-785.
Campbell et al, Nature Genetics 2016 “Distinct patterns of somatic genome alterations in lung adenocarcinomas”
Simanshu, Dhirendra K. et al. “RAS proteins and their regulators in human disease.” Cell 170.1 (2017): 17-33.
January 2019, first patient in Phase 1/2 clinical trial of MRTX849, a direct KRASG12C inhibitor, is dosed and shows first clinical data in October 2019.
SAPPHIRE trial kicks off mid-2019 and begins enrolling patients.
Early in 2020, KRASG12D inhibitor candidates advance into IND-enabling studies.
Rate how well Mirati Therapeutics lives up to its initial vision.
Mirati Therapeutics jobs
Do you work at Mirati Therapeutics?
Is Mirati Therapeutics' vision a big part of strategic planning?
Mirati Therapeutics competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Clovis Oncology | 2009 | $148.8M | 468 | 1 |
| Tango Therapeutics | 2017 | $42.1M | 91 | 9 |
| Salarius Pharmaceuticals | 2011 | $5.2M | 5 | - |
| Cyteir Therapeutics | 2012 | $1.6M | 26 | - |
| Oncternal Therapeutics | 2013 | $785,000 | 13 | - |
| G1 Therapeutics | 2008 | $82.5M | 148 | 2 |
| Onconova Therapeutics | 1998 | $226,000 | 12 | - |
| IDEAYA Biosciences | 2015 | $7.0M | 69 | 6 |
Mirati Therapeutics history FAQs
Zippia gives an in-depth look into the details of Mirati Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Mirati Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Mirati Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Mirati Therapeutics. The data presented on this page does not represent the view of Mirati Therapeutics and its employees or that of Zippia.
Mirati Therapeutics may also be known as or be related to MIRATI THERAPEUTICS INC., Mirati Therapeutics, Mirati Therapeutics Inc, Mirati Therapeutics Inc. and Mirati Therapeutics, Inc.